CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi...
SHANGHAI and HONG KONG, April 29, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...
* Developed in-house by internal R&D Team at Antengene, ATG-018 is an orally-available, small mol...
The company will present the preclinical data of five novel drug candidates at AACR 2022 (onApril 8...
- Results showed an overall response rate (ORR) of 29.3% for all treated patients. - Consistent res...
* This study is the third ATG-016 study to be conducted in China. * Study highlights Antengene's...
SHANGHAI and HONG KONG, March 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...
- The novel bispecific antibody ATG-101 is Antengene's first in house developed molecule with glob...
* Posters Showcase Early-Stage Clinical and Preclinical Pipeline. * Focus on ATG-037, ATG-018, A...
- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed an...
SHANGHAI and HONG KONG, March 2, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...
SHANGHAI and HONG KONG, Feb. 7, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...
SHANGHAI and HONG KONG, Jan. 5, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...
SHANGHAI and HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...
SHANGHAI and HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...
SHANGHAI AND HONG KONG, Dec. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...
SHANGHAI and HONG KONG, Dec. 17, 2021 /PRNewswire/ -- Antengene Corporation Limited (the "Company" ...
SHANGHAI and HONG KONG, Dec. 16, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...
SHANGHAI and HONG KONG, Dec. 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...
* ATG-017 is an oral small molecule ERK1/2 inhibitor; Opdivo® is aPD-1 checkpoint inhibitor * C...